

Discovery of Novel Peptides Targeting *Anopheles Gambiae* Using In Silico Approaches

Venkatajothi Ramarao^{1*}, Kasthuri Natarajan², Rubina Mary A³, Santhosh Venkatesan⁴, Balakrishnan Subramanian⁵ and Yokesh V⁶

^{1*,4}Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai - 602105, Tamil Nadu, India

²Department of Biomedical Sciences, Saveetha college of Allied Health Sciences, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Thandalam, Chennai- 602105, Tamil Nadu, India

³Department of Community Medicine, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai- 602105, Tamil Nadu, India

⁵Department of Biochemistry, Basic Medical Sciences, Michael Chilufya Sata School of Medicine, The Copperbelt University, Ndola, Zambia

⁶Department of Medical Laboratory Technology, Saveetha college of Allied Health Sciences, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Thandalam, Chennai- 602105, Tamil Nadu, India

*Author for Correspondence: Dr. Venkatajothi Ramarao.
drrvjothi10@gmail.com

Received: 15th Dec, 2025; Revised: 9th Feb 2026; Accepted: 12th Feb, 2026; Available Online: 30th March, 2026

ABSTRACT

Pharmaceuticals that employ peptides, or short chains of amino acids, as therapeutic agents are known as peptide-based drugs. These drugs offer a fresh method of treating a range of illnesses by mimicking or blocking the actions of natural proteins, hormones, or enzymes. Human, animal, and bird infections are spread by *Anopheles gambiae*. Humans suffer from several severe health problems as a result. The effectiveness of the peptide derived from *Boerhavia diffusa* against *Anopheles gambiae* was determined in this investigation. We use in silico techniques to analyse the new peptide's insecticidal characteristics. Protein-peptide docking investigations using automated in silico methods were part of the study's methodology. Using sophisticated 3D macromolecular visualization tools, all the data were explained. The effectiveness of the new peptide against *Anopheles gambiae* (African malaria mosquito) was amply demonstrated by the full docking data. The new peptide (SFQALLERIYFHVKIEYLVKVLTKNCRILWLFKDPFTHYIRYQGKSILS) (<https://www.modelarchive.org/doi/10.5452/ma-4whza>) was ultimately found to have superior inhibitory activity against *Anopheles gambiae*. As a result, the de novo peptide functions as a possible treatment for *Anopheles gambiae*.

Keywords: Peptide, *Anopheles gambiae*, drug docking, computational protocols

How to cite this article: amarao V, Natarajan K, Mary RA, Venkatesan S, Subramanian B, Yokesh V, Discovery of Novel Peptides Targeting *Anopheles Gambiae* Using In Silico Approaches. Int J Drug Deliv Technol. 2026;16(3): 132-139. DOI: 10.25258/ijddt.16.3.17

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Due mostly to their great efficiency in transmitting *Plasmodium falciparum*, the most deadly type of malaria, members of the *Anopheles gambiae* mosquito complex have likely caused more human deaths than any other animal¹⁻². Four key factors make this mosquito complex an extremely effective disease vector: (1) they are frequently quite numerous, (2) they bite humans a lot, (3) they are very prone to infection, and (4) they have a long lifespan (for a mosquito)³. At least eight morphologically similar species, the majority of which are largely zoophilic, make up the *Anopheles gambiae* species complex. *Anopheles gambiae* and *Anopheles coluzzii*, two

of the most closely related members of the complex, are the main vectors of malaria because of their propensity to feed on humans, their longevity, the fact that they sleep within traditional thatch-roofed homes, and their relative abundance⁴⁻⁶. While *Anopheles coluzzii* is restricted to West Africa, *Anopheles gambiae* is found across much of sub-Saharan Africa⁷. They share a lot of behavioral characteristics and are the complex's most recently divergent members. Members of the complex may be expanding their range, as evidenced by the recent report of *Anopheles coluzzii* from East Africa⁸.

Soon after dusk, adult anophelines emerge from the pupae and wait for a few minutes before drying themselves and

*Author for Correspondence: drrvjothi10@gmail.com

inflating their wings before taking off⁹. The direction and strength of the wind affect the dispersal flight. Mosquitoes may be carried by the wind if there is a strong dominating breeze, but dispersal may be random if there is little or no wind¹⁰. With a maximum flight speed of 1.4–1.8 ms⁻¹³, 80% of *Anopheles gambiae* on open savanna fly less than one meter above the ground¹¹⁻¹². Circadian rhythms regulate flight, which happens at night¹³⁻¹⁴.

Small-molecule drug design and discovery have found success with computational docking techniques. In the area of peptide therapies, comparable initiatives are underway¹⁵⁻¹⁶. However, the far more flexible and bigger peptide molecules are typically not effectively modeled by the docking techniques created for small-molecule interactions¹⁷. New methods for protein-peptide docking have been developed quickly because of the interest in peptide therapies¹⁸⁻¹⁹ and are increasingly being used in the drug discovery and design process²⁰⁻²⁷. *Plasmodium falciparum* parasites are spread via the main and most effective mosquito vector of malaria in Sub-Saharan Africa, *Anopheles gambiae*. These anthropophilic (human-biting) mosquitoes are a primary target for control techniques like ITNs because they thrive in human surroundings and are therefore very successful at spreading the disease, mostly through nocturnal, indoor feeding. In our current research work, we have developed

a peptide-based medicine which was analyzed using molecular docking studies to control mosquitoes.

MATERIALS AND METHODS

The plant *Boerhavia diffusa* and its novel antigenic peptide was derived to assess its role against *Anopheles gambiae*. Molecular docking was conducted using PDB-IHM database to assess the peptide-protein docking. In silico drug discovery method was done to determine the interaction of compounds with Cytochrome C Oxidase subunit I in *Anopheles gambiae*. Using computational analysis peptide-receptor interactions and its 3D conformation was visualized using discovery studio software.

RESULTS

1.1. Peptide-Protein Docking

To conduct molecular docking experiments, the structure of the novel peptide (ma-4whza) (<https://www.modelarchive.org/doi/10.5452/ma-4whza>) was taken from the PDB-IHM database.

The Cytochrome c Oxidase Subunit 1 (COX1) (*Anopheles gambiae*) protein sequence was made public by the NCBI database (<https://www.uniprot.org/uniprotkb/P34838/entry#sequences>). (Figure 1)




Figure 1: The above pictorial representation depicts the major steps involved in our current research work

Docking of Drugs

One popular in silico drug discovery method, "molecular docking," looks at how tiny compounds interact with Cytochrome c Oxidase subunit 1 in *Anopheles gambiae* to determine their optimal conformations. Docking tests were conducted using peptides and the Cytochrome-C Oxidase subunit 1 (COI). The PatchDock server

(<https://bio3d.cs.huji.ac.il/webserver/patchdock/>) supplied the 3D docked file format of the ligand and receptor sequence (Cytochrome-C Oxidase subunit 1) in order to predict the 3D interaction of the receptor and ligand molecules. The research of the Discovery studio program also shed light on H-bond interactions (Figure 2 and 3).

CYTOCHROME P450 SEQUENCE

> P34838 · COX1_ANOGA

[*Anopheles gambiae* (African malaria mosquito)]

MSRQWLFSTNHKDIGTLYFIFGAWAGMVGTSLSILIRAE LGHPGAFIGDDQIYNVIVTAHAFMIFFMVMPIMI
 GGFGNWLVPMLGAPDMAFPRMNNMSFWMLPSSLTLLISSSMVENGAGTGWTVYPPLSSGIAHAGASVDL
 AIFSLHLAGISSILGAVNFITVINMRSPGITLDRMPLFVWSVVITAVLLLLSLPVLGAIITMLLTDRLNNTSFFD
 PAGGGDPILYQHLFWFFGHPEVYILILPGFGMISHIITQESGKKETFGNLGMIYAMLAIGLLGFIVWAHHMFTV
 GMDVDTRAYFTSATMIAVPTGKIFSWLATLHGTQLTYS PAMLWAFGFVFLFTVGGTLGVVLANS SIDIVLHD
 TYYVVAHFHYVLSMGAVFAIMAGFVHWYPLLTGLTMNPTWLKIQFSIMFVGVNLTFFPQHFLGLAGMPRRY
 SDFPDSYLTWNVVS SSGTISLFAILYFLFIWESMITQRTPAFFPQLSSSIEWYHTLPPAEHTYAELPLLTNNE

Figure 2: Cytochrome P450's amino acid sequence obtained from the UniProt database

BOERHAVIA DIFFUSA PEPTIDE

SFQALLERIYFHVKIEYLVKVLTKNCRILWLFKDPFTH YIRYQGKSILS

Figure 3: Amino acid sequence of the peptide obtained from *Boerhavia diffusa*.

3.3 Peptide-Receptor interactions

Discovery Studio Software, a molecular visualization tool, was used to display the 3D structure along with

cytochrome P450 and molecular drug docking studies on peptides. (Figures 4 – 10)




Figure 4: The 3D structure of cytochrome-C oxidase subunit 1 (COX1) in *Anopheles gambiae* as displayed by Discovery Studio program. The different atoms are represented by different colors.




Figure 5: The 3D structure of a novel peptide using the Discovery Studio software's Space fill model view

Solution number \updownarrow	Score	Area	ACE	PDB file	Show/hide
1	13898	1785.6	-209.99	result.1.pdb	<input checked="" type="checkbox"/>
2	13344	1729.2	-428.19	result.2.pdb	<input type="checkbox"/>
3	13302	2022.2	-473.31	result.3.pdb	<input type="checkbox"/>
4	13244	1633.0	-493.39	result.4.pdb	<input type="checkbox"/>
5	13160	2101.3	-547.0	result.5.pdb	<input type="checkbox"/>
6	12980	2129.0	-330.52	result.6.pdb	<input type="checkbox"/>
7	12378	1736.5	-411.67	result.7.pdb	<input type="checkbox"/>
8	12298	1782.4	-323.36	result.8.pdb	<input type="checkbox"/>
9	12268	2074.3	-527.99	result.9.pdb	<input type="checkbox"/>

Figure 6: PatchDock server results showing the de novo peptide's complex form with *Anopheles gambiae* Cytochrome c Oxidase Subunit 1 (COX1) and the associated binding scores




Figure 7: Using the de novo peptide, a surface model produced using Discovery Studio software displays the 3D complex structure of Cytochrome-C Oxidase (COX1) subunit 1




Figure 8: The 3D H-bond interaction view of cytochrome-C oxidase subunit 1 with the de novo peptide generated by Discovery Studio program, marked with the red colour amino acids at the binding site.




Figure 9: Three-dimensional representation of the Vander Waals interaction between the de novo peptide generated by Discovery Studio software and Cytochrome-C oxidase subunit 1.




Figure 10: Cytochrome c oxidase subunit 1 and the de novo peptide's electrostatic contact as generated by Discovery Studio software.

DISCUSSION

The cytochrome c oxidase subunit 1 of *Anopheles gambiae* has an amino acid length of 514 aa (AB332027.2) (Fig 1). We decided to investigate COX1 since it is essential to the study of dengue. Using in silico techniques, the peptide was isolated from *Boerhavia diffusa* and added to PDB-IHM (<https://www.modelarchive.org/doi/10.5452/ma-4whza>)²⁸.

The total length of the peptide is 50 aa (Fig.2). Using in silico methods, the structure of our unique peptide was transformed from 2D to 3D. Automated drug docking techniques were used to introduce the chosen target protein from *Anopheles gambiae*. The outcomes unequivocally showed that the proteins are inhibited by the newly discovered peptide. Fig. 4 shows the 3D structure of the new peptide with colored atom identifiers.

The three-dimensional structure of the peptide as observed in the space fill model is depicted in Fig. 3 using colored atoms. The three-dimensional structure was visualized using Discovery Studio, a state-of-the-art molecular visualization tool. The internal Vander Waals force determines how the *Anopheles gambiae* target protein for cytochrome c oxidase subunit 1 binds to the chemical structure. PatchDock is a molecular docking technique that relies on geometry²⁹. Its goal is to identify docking changes that produce good complementarity between molecular shapes. Applying such modifications results in minor levels of steric conflicts as well as broad interface areas. Numerous matched local features of the docked molecules with complementary properties are guaranteed to be included in the broad interface. The Connolly dot surface representations of the molecules is separated into concave, convex, and flat patches using the PatchDock algorithm³⁰.

According to our drug evaluations, the novel peptide against Cytochrome c oxidase subunit 1 (*Anopheles gambiae*) has a higher negative value of -262.21 kcal/mol than other medications (Figure 5). According to theoretical Cheminformatics principles, a bigger negative value indicates a good drug-receptor binding relationship. The thorough molecular dynamic studies of Cytochrome c oxidase subunit 1(COX1) against the distinct peptide (Figure 6-9) show that the peptide directly connects with the matching surface binding cavities of the *Anopheles gambiae* protein³¹. Interestingly, we discovered that the (COX1) protein from *Anopheles gambiae* had an overall length of 514 aa. The functional part of the (COX1) sequence is the Cytochrome c oxidase subunit I signature and profile, which is located between amino acids 1-511 [PS50855].

In biological molecules, hydrogen bonds (H-bonds) are among the most important and consequential non-covalent interatomic interactions. They oversee the complementarity of the two strands in DNA and RNA as well as the stabilization of the primary secondary structural components in proteins. The way that enzymes connect with their substrates or products, how antibodies recognize antigens, and numerous other biological processes all depend on H-bonds. The following H-bond interaction amino acid involvement within these borders was clearly shown by the post-docking studies: ARG: 109, PRO: 36, LYS: 520, GLN: 478, ARG: 27, LEU: 468, PHE: 37, THR: 109. All the previously mentioned findings were investigated^{32,33}.

CONCLUSION

In this study, the insecticidal capabilities of a peptide produced from the plant species *Boerhavia diffusa* were examined. The de novo peptide was docked with the protein target, which in this case was *Anopheles gambiae* Cytochrome c oxidase subunit 1 (COX1). The collective findings unequivocally demonstrated that the peptide's molecular interactions with *Anopheles gambiae* Cytochrome c oxidase subunit 1 (COX1) occur within the domain ranges. According to our investigation, our modeled peptide with the following sequence

(SFQALLERIYFHVKIEYLVKVLTKNCRILWLFKDPF THYIRYQGKSILS) possesses insecticidal capabilities. It can therefore be used as a peptide-based pesticide. This drug can be used in spays to control mosquitoes because the peptide's source is a natural substance.

ACKNOWLEDGEMENTS

The authors extend their appreciation to the management of Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, for encouragement of this work.

Source of support: Nil.

Conflict of interest: There is no conflict of interest among authors.

REFERENCES

1. Boyd MF. A comprehensive survey of all aspects of this group of diseases from a global standpoint. *Malaria*, 1949;1:3-25. doi:10.1001/jama.1950.02910420078036.
2. Gillies, MT, W.H. Wernsdorfer, I.A. McGregor editors. *Malaria: principles and practice of malariology*. 1988;1:453-485. Doi: 10.1017/S0031182000078811.
3. Arumugam G, Saravu K, Kotthapalli P, Nallapati VT, Bhat P, Achari M, Kulal N, Ananganallur Nagarajan S, SL H, Kumar A. Mosquito prevalence, resting habitat preference, and Plasmodium infection status of anophelines in coastal Karnataka during the declining phase of malaria—an exploratory study. *Parasitology Research*. 2024; 123(8):308.
4. Coetzee M. Distribution of the African malaria vectors of the *Anopheles gambiae* complex. *The American journal of tropical medicine and hygiene*. 2004;70(2):103-104. (<https://doi.org/10.4269/ajtmh.2004.70.103>).
5. Bhuvaneshwari A, Shriram AN, Raju KH, Kumar A. Mosquitoes, lymphatic filariasis, and public health: A systematic review of *Anopheles* and *Aedes* surveillance strategies. *Pathogens*. 2023;12(12):1406.
6. Konate L, Faye O, Diallo M, Dia I. Vector bionomics and malaria transmission in an area of sympatry of *An. arabiensis*, *An. coluzzii* and *An. gambiae*. *Acta tropica*. 2019;189:129-136. (<https://doi.org/10.1016/j.actatropica.2018.10.005>).
7. Sinka ME, Golding N, Massey NC, Wiebe A, Huang Z et al. Modelling the relative abundance of the primary African vectors of malaria before and after the implementation of indoor, insecticide-based vector control. *Malaria journal*. 2016;15(1):142. (<https://doi.org/10.1186/s12936-016-1187-8>).
8. Kamau L, Bennett KL, Ochomo E, Herren J, Agumba S et al. The *Anopheles coluzzii* range extends into Kenya: Detection, insecticide resistance profiles and population genetic structure in relation to

- conspicuous populations in West and Central Africa. 2024;122. (<https://doi.org/10.21203/rs.3.rs-3953608/v1>).
9. Reiter P and Jones MDR. An eclosion timing mechanism in the mosquito *Anopheles gambiae*. *Journal of Entomology Series A, General Entomology*. 1976;50(3):161-168. (<https://doi.org/10.1111/j.1365-3032.1976.tb00131.x>).
 10. Lindsay SW, Schellenberg JA, Zeiler HA, Daly RJ, Salum FM et al. Exposure of Gambian children to *Anopheles gambiae* malaria vectors in an irrigated rice production area. *Medical and veterinary entomology*. 1995;9(1):50-58. (<https://doi.org/10.1111/j.1365-2915.1995.tb00116.x>).
 11. Gillies MT, Wilkes TJ. The effect of high fences on dispersal of some West-African mosquitoes (Diptera-Culicidae). *Bull Entomol Res*. 1978;68:401-408. (<https://doi.org/10.1017/S000748530000938X>).
 12. Snow WF. Studies of house-entering habits of mosquitoes in The Gambia, West Africa: experiments with prefabricated huts with various wall apertures. *Med Vet Entomol*. 1987; 1:9-21. (<https://doi.org/10.1111/j.1365-2915.1987.tb00318.x>).
 13. Gillies MT, Wilkes TJ. Field experiments with a wind-tunnel on the flight speed of some West-African Mosquitoes (Diptera, Culicidae). *Bull Entomol Res*. 1981;71:65-70. (<https://doi.org/10.1017/S0007485300051038>).
 14. Jones MDR, Gubbins SJ. Changes in the circadian flight activity of the mosquito *Anopheles gambiae* in relation to insemination, feeding and oviposition. *Physiol Entomol*. 1978; 3: 213-220. (<https://doi.org/10.1111/j.1365-3032.1978.tb00151.x>).
 15. Meenakshisundaram N, Sajiv G. Experimental analysis of malarial parasites infection by using deep learning based on medical image processing logic. In 2025 3rd International Conference on Integrated Circuits and Communication Systems (ICICACS) 2025 Feb 21 (pp. 1-5). IEEE.
 16. Russo A, Scognamiglio PL, Hong Enriquez RP, Santambrogio C, Grandori R et al. In silico generation of peptides by replica exchange Monte Carlo: Docking-based optimization of maltose-binding-protein ligands. *PLoS One*. 2015;10(8):e0133571. (<https://doi.org/10.1371/journal.pone.0133571>).
 17. Mahdavi M, Moreau V. In silico designing breast cancer peptide vaccine for binding to MHC class I and II: a molecular docking study. *Computational biology and chemistry* 2016;65:110-116. (<https://doi.org/10.1016/j.compbiolchem.2016.10.007>).
 18. Redko B, Tuchinsky H, Segal T, Tobi D, Luboshits G et al. Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma. *Oncotarget*. 2016;8(1):757. (<https://doi.org/10.18632/oncotarget.12748>).
 19. Cao HL, Chen H, Cui YH, Tian HL, Chen J. Structure-based design and confirmation of peptide ligands for neuronal polo-like kinase to promote neuroregeneration. *Computational Biology and Chemistry*. 2016;61:238-244. (<https://doi.org/10.1016/j.compbiolchem.2016.02.012>).
 20. Liu T, Pan X, Chao L, Tan W, Qu S et al. Subangstrom accuracy in pHLA-I modeling by Rosetta FlexPepDock refinement protocol. *Journal of chemical information and modeling*. 2014;54(8):2233-2242. (<https://doi.org/10.1021/ci500393h>).
 21. Li Y, Liu X, Dong X, Zhang L, Sun Y. Biomimetic design of affinity peptide ligand for capsomere of virus-like particle. *Langmuir*. 2014;30(28):8500-8508. (<https://doi.org/10.1021/la5017438>).
 22. Kar RK, Gazova Z, Bednarikova Z, Mroue KH, Ghosh A et al. Evidence for inhibition of lysozyme amyloid fibrillization by peptide fragments from human lysozyme: a combined spectroscopy, microscopy, and docking study. *Biomacromolecules*. 2016;17(6):1998-2009. (<https://doi.org/10.1021/acs.biomac.6b00165>).
 23. Menegatti S, Bobay BG, Ward KL, Islam T, Kish WS et al. Design of protease-resistant peptide ligands for the purification of antibodies from human plasma. *Journal of Chromatography A*. 2016;1445:93-104. (<https://doi.org/10.1016/j.chroma.2016.03.087>).
 24. Alam N, Schueler-Furman O. Modeling peptide-protein structure and binding using Monte Carlo sampling approaches: Rosetta FlexPepDock and FlexPepBind. In *Modeling Peptide-Protein Interactions: Methods and Protocols*. 2017;139-169. New York, NY: Springer New York. (https://doi.org/10.1007/978-1-4939-6798-8_9).
 25. Pierce BG, Weng Z. A flexible docking approach for prediction of T cell receptor-peptide-MHC complexes. *Protein Science*. 2013;22(1):35-46. (<https://doi.org/10.1002/pro.2181>).
 26. Balaji M. Identification of the mutated sites present in the transmembrane regions of Scn1A_Human (Sodium Voltage-Gated Channel Alpha Subunit 1) using in silico techniques. *International Journal*. 2020;5(1):1-6. (<https://doi.org/10.26452/ijpib.v5i1.1149>).

27. Mario Prateek Selvam, Nisha Muthukumar, Sangamithra Senthilkumar, Sandhiya Vaidhyalingam K. Dharshene, Kasthuri Natarajan and S. Rupachandra. In Vitro Assessment of Cytotoxic Activity of Bioactive Peptides from Momordica Dioica and Solanum Trilobatum against Human Colon Cancer Cells. *Biomedical and Pharmacology Journal*; 2021;14(2):1007-1018. (<https://dx.doi.org/10.13005/bpj/2202>).
28. Venkatajothi Ramarao, Munivelan, B. 3D peptide-protein docking between a novel peptide derived from Boerhavia diffusa and a cervical cancer protein, transmembrane protein 50a (tm50a), using in silico strategies. *International journal of applied*. 2025;11(2):293-298. (<https://doi.org/10.22271/allresearch.2025.v11.i2d.12376>).
29. Nithya G and Prabha V. Identification of a plant derivative (*Hibiscus cannabinus*) for mosquito (*Anopheles darlingi*) control using in silico protein-protein docking techniques. 2023. <https://doi.org/10.22271/23487941.2023.v10.i4a.683>
30. Connolly M.L. Solvent-accessible surfaces of proteins and nucleic acids. *Science*. 1983; 221: 709–713.
31. Nijanthi P, Santhi S, Munivelan B. Molecular dynamics studies on the arginine kinase protein of *Aedes sollicitans*: against the natural chemical compound, Gedunin. 2023. <https://doi.org/10.22271/23487941.2023.v10.i2a.665>
32. Venkatajothi Ramarao, M Mohamed Mahroop Raja, Vijayalakshmi Kandasamy. Discovery of a de novo medicine derived from peptide against *Culex quinquefasciatus* using computational protocols. *International Journal of Mosquito Research* 2025; 12(3):32-36. (<https://www.doi.org/10.22271/23487941.2025.v12.i3a.838>).
33. Astalakshmi P, John MB, Kavinilavu G, Vimala D. In silico study on hexadecanoic acid against the outer membrane protein transport protein of *Culex quinquefasciatus* and *Aeromonas hydrophila*. 2023. (<https://doi.org/10.22271/23487941.2023.v10.i4a.680>).